Leerink Partners analyst Michael Schmidt weighed in on Juno Therapeutics (NASDAQ: JUNO) after the company announced that it placed the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE